NGeneBio Co

NGeneBio Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 14.32 M KRW. In the previous year, Stock-Based Compensation (SBC) was 43.22 M KRW — a change of -66.87% (lower).

Stock-Based Compensation

14.32 MKRW

YoY

-66.87%

Last updated:

Stock-Based Compensation (SBC) of NGeneBio Co is 2025 14.32 M KRW. Stock-Based Compensation (SBC) of NGeneBio Co was 2024 43.22 M KRW. It decreases by -66.87% lower compared to the previous year.

The NGeneBio Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2020
441.81 M KRW
Jan 1, 2021
501.98 M KRW
Jan 1, 2022
241.31 M KRW
Jan 1, 2023
195,000.00 KRW
Jan 1, 2024
43.22 M KRW
Jan 1, 2025
14.32 M KRW
The NGeneBio Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
14.32 MKRW-66.87%
43.22 MKRW+22,063.59%
195,000.00KRW-99.92%
241.31 MKRW-51.93%
501.98 MKRW+13.62%
441.81 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Stock-Based Compensation (SBC) of NGeneBio Co is 14.32 M KRW in 2025.

Stock-Based Compensation (SBC) of NGeneBio Co changed from 43.22 M KRW to 14.32 M KRW, representing a -66.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s NGeneBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NGeneBio Co

All Key Metrics — NGeneBio Co